Europe Vaccines Market Size and Forecast (2021 - 2031)

The Europe Vaccines Market is projected to grow significantly, reaching approximately US$ 35,815.1 million by 2031, up from US$ 24,528.3 million in 2024, with an estimated compound annual growth rate (CAGR) of 5.6% from 2025 to 2031.

Executive Summary and Market Analysis

According to the Annual Epidemiological Report from the European Centre for Disease Prevention and Control (ECDC) published in April 2025, there were 35,212 reported cases of measles in the European Union (EU) and European Economic Area (EEA) in 2024, marking a tenfold increase from the 3,973 cases in 2023. This resurgence followed a seasonal pattern, contrasting with the atypical trends observed from 2021 to 2023, when measles cases were unusually low due to the COVID-19 pandemic. The ECDC recommends that to effectively prevent measles outbreaks, at least 95% of the eligible population should receive two doses of the measles, mumps, and rubella (MMR) vaccine. However, as of July 2025, only Hungary, Malta, Portugal, and Slovakia achieved this target within the EU/EEA, highlighting a growing demand for vaccines to combat rising infection rates.

Strategic Insights

Market Segmentation

The Europe Vaccines Market is categorized as follows:

• By Type: Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugated Vaccines segment dominated the market in 2024.
• By Indication: HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Others. The HPV segment was the largest in 2024.
• By Route of Administration: Injection, Oral, and Others. The injection route held the largest market share in 2024.
• By Age Group: Pediatric and Adult. The pediatric segment was the largest in 2024.

Market Outlook

The vaccine industry is undergoing a transformative phase, with combination and therapeutic vaccines emerging as key opportunities for manufacturers. Combination vaccines, which protect against multiple diseases in a single dose, are expanding beyond pediatric use to include adults and the elderly, particularly for respiratory illnesses like influenza and COVID-19. These vaccines can significantly enhance immunization rates and reduce disease burden. By 2030, combination vaccines are expected to protect against 30 infections with fewer doses, with major pharmaceutical companies like Moderna, Pfizer/BioNTech, and others developing these innovative products.

Therapeutic vaccines, designed to treat existing conditions rather than prevent them, represent a new frontier in vaccine technology. They utilize advancements in mRNA and personalized medicine to stimulate the immune system against diseases such as cancer and chronic infections. As of 2024, the FDA has approved several therapeutic vaccines, and ongoing research is expected to expand this segment significantly.

Country Insights

The market is segmented by country, with Germany holding the largest share in 2024. Germany is a key research hub with numerous pharmaceutical and biotechnology companies focused on developing therapies for various conditions. Initiatives like the DZIF (German Center for Infection Research) and funding for vaccine development projects underscore Germany's commitment to enhancing pandemic preparedness and advancing vaccine technology.

Company Profiles

Key players in the Europe Vaccines Market include Abbott Laboratories, GSK Plc, Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, CSL Ltd, Serum Institute of India Pvt Ltd, BioNTech SE, and Sinovac Biotech Ltd. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence. Show more